Newly Validated Q175 Knock-in Model Better Indicator of Huntington’s Disease Condition in Humans
June 8, 2012 - Huntington's disease (HD) is an autosomal neurodegenerative disorder, characterized by severe behavioral, cognitive and motor deficits. Several mouse models, including the R6/2 mouse, which expresses a truncated fragment of mHTT, have been generated to examine the pathogenesis of the disease in an effort to develop novel treatment options. The newly validated Q175 knock-in mouse, however, carries the mutation in its appropriate genomic and protein context, making it, mechanistically, the most true-to-life model of the human condition.
Charles River Discovery Research Services has licensed and validated the Q175 knock-in mouse model, a new tool for researchers investigating the effects of HD therapeutics. This model is a counterpart to the widely used R6/2 mouse line, which demonstrates very fast progression of HD-like symptoms. In contrast, the Q175 mouse develops symptoms early, and with slower progression, allowing ample time to observe the early events triggered by the mutation. Full manifestation of HD-like motor deficits and brain atrophy is apparent in homozygote mice from 3 months and in heterozygote littermates by 4 to 8 months of age. The robustness, gene dose-dependency, progression and early-onset alterations in the Q175 pathogenesis provide researchers with a longer window to detect chronic compound administration effects. Charles River’s mouse efficacy test paradigm includes behavior and cognition, in vivo magnetic resonance imaging (MRI) for brain volumetry and magnetic resonance spectroscopy (MRS) for brain metabolites. Additional testing services are described below.
Behavioral and Cognitive Tests for Huntington’s Disease
For more information about facilitating your Huntington’s disease study with Charles River’s Q175 knock-in model, please contact us at firstname.lastname@example.org.
For more information, contact us at:
*indicates a required field.
The information you provided will be kept confidential.
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.
We offer a package of well-established, state of the art in vitro mode of action assays that are suitable for early phase biocomparability studies, lot release and stability. These tests can accelerate the time it takes to get a new product ready for market submission.
May 21–May 24
RDD Europe 2013 is a forum for pulmonary and nasal drug delivery experts from all around the world to exchange scientific knowledge and expertise.
May 23–May 23
This full-day seminar encompasses selected topics from our Charles River Short Course on Laboratory Animal Science. We would like to acknowledge Michigan State University for hosting this event and extend our heartfelt thanks to guest speaker Dr. Danielle Ferguson.
This position is responsible for serving as a as a study director (SD), project scientist (PS) and/or principal investigator (PI) in the direction and execution of assigned studies in compliance with GLP regulations as they apply to the conduct of nonclinical research; coordinating all phases of the study planning process with appropriate departments; generating high-quality project plans, protocols, amendments and reports appropriate for assigned studies; reviewing, interpreting, integrating and presenting data on assigned studies; and functioning as contact for the planning and execution of sponsor interaction related to assigned studies, including proposal management and study scheduling, conduct and reporting.
This position is responsible for managing international aspects of US Federal income tax compliance; assisting with international tax planning, including identification of planning opportunities, designing and implementing plans, and transfer pricing process; overseeing quarterly ETR forecast process; and participating in the tax provision process, including assessment of tax risks, documentation of key positions, and review of non-US tax provision submissions.
Charles River Laboratories, Inc.